IP Library › Granted Patent US 10,400,261
Granted Patent B2
US 10,400,261 · App. 15/962,782 · Granted Sep 3, 2019

Genetically transformed yeasts capable of producing a molecule of interest at a high titre

Inventors: Corinne Brocard-Masson (Paris, FR); Isabelle Bonnin (Paris, FR); Bruno Dumas (Paris, FR)
Assignee: SANOFI
C12P33/00C07K14/79C12N1/14C12N1/16C12N9/0006C12N9/0079C12N9/0081C12N15/81C12Y101/01051
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,400,261
App. No.
15/962,782
Granted
Sep 3, 2019
Kind
B2
Abstract

The subject of the present invention is a process for preparing a genetically modified yeast by multicopy integration of at least four expression cassettes, allowing the production of a molecule of interest at high titer. The subject of the present invention is also yeasts transformed according to said process, and the use thereof for producing hydrocortisone.

Claims (26)

1. A yeast isolate comprising:

multiple copies of two integration plasmids stably integrated into chromosome XII or chromosome IV, wherein each integration plasmid comprises at least two expression cassettes, such that the two integration plasmids together comprise at least four expression cassettes, wherein the four expression cassettes of the two integration plasmids are P450scc, adrenodoxin (ADX), P450c11, and 3β-hydroxysteroid dehydrogenase (3β-HSD); and

wherein the yeast isolate produces at least 100 mg/L hydrocortisone.

2. The yeast isolate of claim 1 , wherein from 5 to 20 copies of the integration plasmids are stably integrated into chromosome XII or chromosome IV.

3. The yeast isolate of claim 2 , wherein from 8 to 12 copies of the integration plasmids are stably integrated into chromosome XII or chromosome IV.

4. The yeast isolate of claim 1 , wherein the multiple copies of each of the integration plasmids are integrated in tandem.

5. The yeast isolate of claim 1 , wherein the yeast isolate is Saccharomyces cerevisiae.

6. The yeast isolate of claim 1 , wherein at least one of the integration plasmids comprises an auxotrophic selectable marker.

7. The yeast isolate of claim 6 , wherein the auxotrophic marker is selected from the group consisting of ADE2, URA3, HIS3, LEU2, TRP1, and LYS2.

8. The yeast isolate of claim 7 , wherein one of the integration plasmids comprises URA3 and the other integration plasmid comprises ADE2.

9. The yeast isolate of claim 7 , wherein at least one of the integration plasmids comprises a selectable marker which is a resistance marker.

10. The yeast isolate of claim 9 , wherein the resistance marker is selected from the group consisting of natMX, phMX, and KanMX.

11. The yeast isolate of claim 1 , wherein at least 85% of a steroid produced by the yeast isolate is hydrocortisone.

12. A yeast isolate comprising:

5-20 copies of two integration plasmids stably integrated into the chromosomes of the yeast isolate, wherein each integration plasmid comprises at least two expression cassettes, such that the two integration plasmids together comprise at least four expression cassettes, wherein the four expression cassettes of the two integration plasmids are P450scc, adrenodoxin (ADX), P450c11, and 3β-hydroxysteroid dehydrogenase (3β-HSD); and

wherein the yeast isolate produces at least 100 mg/L hydrocortisone.

13. The yeast isolate of claim 12 , wherein from 8 to 12 copies of the integration plasmids are stably integrated into the chromosomes of the yeast isolate.

14. The yeast isolate of claim 12 , wherein the 5 to 20 copies of the two integration plasmids are integrated into the chromosomes of the yeast isolate in tandem.

15. The yeast isolate of claim 12 , wherein the 5 to 20 copies of the integration plasmids are integrated on chromosome XII or IV of the yeast isolate.

16. The yeast isolate of claim 12 , wherein the yeast isolate is Saccharomyces cerevisiae.

17. The yeast isolate of claim 12 , wherein at least one of the integration plasmids comprises an auxotrophic selectable marker.

18. The yeast isolate of claim 17 , wherein the auxotrophic marker is selected from the group consisting of ADE2, URA3, HIS3, LEU2, TRP1, and LYS2.

19. The yeast isolate of claim 18 , wherein one of the integration plasmids comprises URA3 and the other integration plasmid comprises ADE2.

20. The yeast isolate of claim 12 , wherein at least one of the integration plasmids comprises a selectable marker which is a resistance marker.

21. The yeast isolate of claim 20 , wherein the resistance marker is selected from the group consisting of natMX, phMX, and KanMX.

22. The yeast isolate of claim 12 , wherein at least 85% of a steroid produced by the yeast isolate is hydrocortisone.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2023
From: SANOFI
To: EUROAPI FRANCE
Reel/Frame 065978/0292 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2019
From: BONNIN, ISABELLE; BROCARD-MASSON, CORINNE; DUMAS, BRUNO
To: SANOFI
Reel/Frame 049819/0455 →
Priority Claims (1)
FR 11 55462 · Jun 21, 2011 · national
Continuity (2)
Division 14127396
Related Publication 20180245120A1 · Aug 30, 2018